Posts Tagged 'Onglyza'

FDA: DPP-4 Inhibitors Like Januvia May Cause Severe Joint Pain

fda issues warning on DPP-4 inhibitorsThe U.S. Food and Drug Administration (FDA) has issued a safety communication warning that certain type 2 diabetes drugs, called dipeptidyl peptidase-4 (DPP-4) inhibitors, may lead to severe joint pain in patients taking them. Among the diabetes drugs named in the announcement are Merck’s Januvia (sitagliptin) and AstraZeneca and Bristol-Myers Squibb’s Onglyza (saxagliptin); as well as Incretin mimetic drugs containing linagliptin or alogliptin.

Januvia was approved by the FDA ...

continue reading...

FDA Panel Recommends Heart Warning for Onglyza

FDA suggests heart warning for onglyzaThe FDA is recommending that the pharmaceutical giant AstraZeneca include information about increased risk of heart failure on the label of its diabetes drug Onglyza.

An FDA advisory panel met on April 14 to discuss data linking AstraZeneca’s Onglyza, as well as Takeda’s diabetes drug, Nesina, to increased risk of hospitalization due to heart failure. According to Bloomberg, 14 of 15 panel members voted in favor of recommending that AstraZeneca add ...

continue reading...

FDA: AstraZeneca’s Diabetes Drug Onglyza May Pose Increased Risk of Death

onglyza may cause risk of heart failureA new FDA report has concluded that AstraZeneca’s new diabetes drug Onglyza may be associated with an increased risk of death, Reuters reports.

This is not the first time AstraZeneca has come under scrutiny for its anti-diabetic drugs. As early as 2008, the FDA began receiving reports of hemorrhagic and necrotizing pancreatitis developing in patients taking AstraZeneca’s incretin mimetic drug Byetta, used to treat type 2 diabetes. ...

continue reading...

Pharmaceutical company tries to hide lobbying

An item on the blog Pharmalot examines an e-mail suggesting that drugmaker Bristol-Myers Squibb plans to get physicians to lobby state Medicaid programs on the company’s behalf.

According to Pharmalot, the e-mail was sent to the district business manager team with the goal of getting Medicaid programs in Pennsylvania, Delaware and Maryland to place the Onglyza diabetes drug on the state formularies.

Although the blog doesn’t say that the company was doing anything illegal, it does point out that the region business ...

continue reading...

Diabetics warned about drug to lower blood sugar

An Irish newspaper, the Evening Herald, reports that diabetics in Europe have been warned about a drug used to lower blood sugar, which has been linked to severe side-effects.

According to the report, patients have suffered “serious hypersensitivity reactions” including anaphylactic shock and acute pancreatitis.

Both the Irish Medicines Board and the European Medicines Agency issued warnings about the drug saxagliptin, which has the brand name Onglyza, prescribed for patients with Type 2 diabetes as part of a diet and exercise program ...

continue reading...